First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Table 1 Clinical presentation, immunophenotype, and cytogenetics

Age/gender	Initial sites of involvement	Immunophenotype						Cytogenetics	Molecular study
Age/gender	Initial sites of involvement	CD4	CD56	CD123	TdT	MPO	Other positive	Cytogenetics	Molecular study
10 years/F	Skin, BM	+	+	+	–	–	CD43, CD45, TCL-1, S100	45, XX, t (1;6), (q21; q23), − 9, add (11) (q23), + 16, − 21	N/A
12 years/F	Skin, LN	+	+	+	Focal	–	CD43, CD45, TCL-1, S100, CD99	46, XX	NRAS G12R, Myb-PLEKH01
15years/F	SC, BM	+	+	+	+	–	CD45, CD5,CD7, CD11c, CD38, CD64	46, XX, t (12;18) (p13; q21), chr. 6 tetraploidy, ETV6 del	N/A

ISSN: 1756-8722